In ovarian cancer, expression of NAPRT, the key enzyme in the Preiss-Handler pathway, correlated with a BRCA-ness gene expression signature, and cells carrying these features were more sensitive to NAMPT inhibitors (99). The gene discussed is NAMPT; the disease is ovarian carcinoma.